{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Challenges
Harmony Biosciences Holdings, Inc. has experienced a notable decline in stock performance, with a significant drop over the past year and three years compared to the S&P 500. Technical indicators suggest a bearish sentiment, reflecting ongoing challenges for the company in the competitive Pharmaceuticals & Biotechnology sector.
Is Harmony Biosciences Holdings, Inc. technically bullish or bearish?
As of October 3, 2025, Harmony Biosciences Holdings, Inc. is in a bearish trend, indicated by negative MACD readings, bearish Bollinger Bands, and underperformance against the S&P 500, with a year-to-date return of -22.73% compared to the S&P 500's 14.18%.
Harmony Biosciences Forms Death Cross, Signaling Bearish Trend Ahead
Harmony Biosciences Holdings, Inc. has recently encountered a technical event known as a Death Cross, indicating a potential bearish market sentiment. Various technical indicators, including MACD and Bollinger Bands, reflect a predominantly bearish outlook, while the stock has underperformed significantly compared to the S&P 500 over the past year.
Is Harmony Biosciences Holdings, Inc. technically bullish or bearish?
As of October 3, 2025, Harmony Biosciences Holdings, Inc. is in a bearish trend, indicated by negative signals from MACD, Bollinger Bands, and moving averages, with a 1-month return of -27.31% compared to the S&P 500's 4.15%.
Is Harmony Biosciences Holdings, Inc. technically bullish or bearish?
As of October 3, 2025, Harmony Biosciences Holdings, Inc. is in a bearish trend, indicated by negative signals from MACD, Bollinger Bands, and moving averages, and has significantly underperformed the S&P 500 with a 1-month return of -27.31% compared to 4.15%.
Harmony Biosciences Hits New 52-Week Low at $26.26
Harmony Biosciences Holdings, Inc. recently hit a 52-week low of USD 26.26, reflecting a one-year performance decline of 10.03%. With a market capitalization of approximately USD 2,061 million, the company has a P/E ratio of 13.00 and a return on equity of 23.40%, but does not offer dividends.
Harmony Biosciences Hits 52-Week Low at $26.35 Amid Market Struggles
Harmony Biosciences Holdings, Inc. has reached a new 52-week low of USD 26.35, reflecting a 1-year performance decline of 9.63%. The company, with a market capitalization of USD 2,061 million, has a P/E ratio of 13.00 and a return on equity of 23.40%, but does not offer dividends.
Harmony Biosciences Hits Day Low of $26.61 Amid Price Pressure
Harmony Biosciences Holdings, Inc. faced notable stock volatility on September 24, 2025, with a significant decline. Over the past week and month, the stock has dropped considerably, reflecting ongoing challenges. However, the company shows strong management efficiency and healthy long-term growth in net sales, alongside high institutional holdings.
Is Harmony Biosciences Holdings, Inc. technically bullish or bearish?
As of September 9, 2025, Harmony Biosciences Holdings, Inc. shows a mildly bullish trend, supported by daily moving averages and KST indicators, but caution is advised due to mildly bearish weekly MACD and Dow Theory, with the stock underperforming the S&P 500 year-to-date.
Is Harmony Biosciences Holdings, Inc. overvalued or undervalued?
As of August 5, 2025, Harmony Biosciences Holdings, Inc. has a very attractive valuation with a low P/E ratio of 13 and favorable EV to EBITDA of 7.96, despite underperforming the S&P 500 with a one-year return of -14.89%.
Is Harmony Biosciences Holdings, Inc. overvalued or undervalued?
As of March 11, 2024, Harmony Biosciences Holdings, Inc. is considered undervalued with an attractive valuation grade, featuring a P/E ratio of 13, an EV to EBITDA of 7.96, and a high ROCE of 46.44%, positioning it favorably against peers like Corcept Therapeutics and Prestige Consumer Healthcare, despite a year-to-date return of -7.21% compared to the S&P 500's 2.44%.
Is Harmony Biosciences Holdings, Inc. technically bullish or bearish?
As of June 13, 2025, the market trend is mildly bearish, supported by daily moving averages and weekly Bollinger Bands, despite mixed signals from the MACD and KST indicators.
What does Harmony Biosciences Holdings, Inc. do?
Harmony Biosciences Holdings, Inc. is a pharmaceutical company specializing in therapies for central nervous system disorders, particularly narcolepsy. As of March 2025, it reported net sales of $185 million and a net profit of $46 million, with a market cap of approximately $1.86 billion.
How big is Harmony Biosciences Holdings, Inc.?
As of Jun 18, Harmony Biosciences Holdings, Inc. has a market capitalization of 1,864.57 million, with net sales of 744.85 million and a net profit of 152.72 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
